



1 November 2021

# Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt

# Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 3 November 2021 or when the announcement is released to the market.

## **Issued by**

Melissa Kostopoulos Compliance Adviser, Listings Compliance (Melbourne)



## ASX RELEASE

#### 1st November 2021

#### By email: melissa.kostopoulos@asx.com.au

Melissa Kostopoulos Adviser, Listings Compliance (Melbourne) ASX Limited

Dear Melissa

## **Request for a trading halt**

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

The Company has received a response from the Food & Drug Administration (**FDA**) which it is currently having its regulatory consultants review. Accordingly pursuant to ASX Listing Rule 17.1, the Company requests the trading halt in order to finalise its review and update to the market.

The Company requests that the trading halt remains in place until the earlier of the Company making an announcement in relation to the received FDA response or commencement of trading on Wednesday 3<sup>rd</sup> November 2021.

The Company is not aware of any reason why the trading halt should not be granted.

Authorised for release on behalf of the Board of Paradigm Biopharmaceuticals Limited

Yours faithfully,

Ku

Kevin Hollingsworth

**Company Secretary**